Drug dosage individualization based on a random-effects linear model. - Wikidata - awgldk - TriplyDB

Drug dosage individualization based on a random-effects linear model.

Drug dosage individualization based on a random-effects linear model.

http://www.wikidata.org/entity/Q34261199

about

Role of Statistical Random-Effects Linear Models in Personalized Medicine Individualizing drug dosage with longitudinal data.Can valproic acid be an inducer of clozapine metabolism?Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies Measuring the individual benefit of a medical or behavioral treatment using generalized linear mixed-effects models.Random-effects linear modeling and sample size tables for two special crossover designs of average bioequivalence studies: the four-period, two-sequence, two-formulation and six-period, three-sequence, three-formulation designs.Estimating individual benefits of medical or behavioral treatments in severely ill patients.

P2860

Q24617125-433A3AFB-A609-4967-A41E-ECFFA5608C1E Q31108602-D1F5194B-1D3D-4FEF-A1F2-D9F60DC10E10 Q34497477-778492DE-DD03-4718-903D-F62C28BCEEAA Q36537180-9033FD55-3784-41CC-9B79-F6F48F2DE72E Q39669644-A78E271A-2D6F-418F-A3B5-2BA094AE7CAC Q45250005-B1516DF9-29F9-4AB6-957D-7A4DD86423BD Q47630719-91C5C5C4-B99C-4941-952F-25DCAD9D88E2

P2860

Drug dosage individualization based on a random-effects linear model.

http://www.wikidata.org/entity/Q34261199

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Drug dosage individualization based on a random-effects linear model.

@ast

Drug dosage individualization based on a random-effects linear model.

@en

Drug dosage individualization based on a random-effects linear model.

@nl

type

label

Drug dosage individualization based on a random-effects linear model.

@ast

Drug dosage individualization based on a random-effects linear model.

@en

Drug dosage individualization based on a random-effects linear model.

@nl

prefLabel

Drug dosage individualization based on a random-effects linear model.

@ast

Drug dosage individualization based on a random-effects linear model.

@en

Drug dosage individualization based on a random-effects linear model.

@nl

P1433

Q34261199-4D2C595D-DCD5-456B-ADA8-EC327B2CD7C1

P1476

Q34261199-2B64E794-F1B9-4881-B34E-586E01C2895A

P2093

Q34261199-1A0E03C9-C55B-43B0-B942-387754A6C604

Q34261199-42AB2EA8-C43B-4B69-8979-78D058ED2805

Q34261199-52F88CCC-C90B-4DDB-A153-A131813DD164

Q34261199-849A7E49-758E-4ACD-9E79-BF7E953F9557

Q34261199-C0154D52-FEA3-4EEC-9007-C70EDB026A50

Q34261199-C9CA0831-7A6B-4B58-9192-38C0D8FA84FF

P2860

Q34261199-1266A4B4-00F0-4AF2-B4F9-DF81F872FB16

Q34261199-523C2D6D-0EE9-44BE-B0E2-E5E7F5A26C5A

Q34261199-52DD4D2A-09FD-4355-B5EB-1491EC4D666C

Q34261199-591C8EE2-80C6-4E32-B3C7-A9F2E5907D99

Q34261199-6E8EE10D-54ED-44CC-A8EC-A94159547A31

Q34261199-932A8E7D-CC3D-4653-9095-67E93E52A1DA

Q34261199-D691ABAF-8AB8-4C29-8992-45895F0B1396

Q34261199-E8D0B552-57BF-4152-ACE0-DD69B60F6620

Q34261199-ED7766B6-1EFE-46B5-9158-0F77D59C9E0E

Q34261199-EE0A6548-033E-4D50-B116-F7449D838279

P304

Q34261199-7B6B6BD1-1924-493A-99AE-4CB62DDDFEDA

P31

Q34261199-1A5629B2-D787-4EB0-A770-CA80F81EB554

P356

Q34261199-1F69B19A-25A4-4D54-AF22-8FBE1DE5FB8B

P433

Q34261199-564D3F90-CFFD-4B35-8581-0A04D250A80D

P478

Q34261199-37E0C06B-10D7-4399-A95F-A0A403C2F07D

P577

Q34261199-5FBA6B45-6765-4650-BFCA-39008AAAF55D

P5875

Q34261199-A65D7A0B-02DC-4862-8B8D-4C057AD07DCC

P698

Q34261199-16E13433-7BE1-434C-A80D-5D02972946FE

P356

10543406.2010.547264

P1433

Journal of Biopharmaceutical Statistics

P1476

Drug dosage individualization based on a random-effects linear model.

@en

P2093

Diego M Rendon

http://www.w3.org/2001/XMLSchema#string

Edoardo Spina

http://www.w3.org/2001/XMLSchema#string

Francisco J Diaz

http://www.w3.org/2001/XMLSchema#string

Jose de Leon

http://www.w3.org/2001/XMLSchema#string

Myladis R Cogollo

http://www.w3.org/2001/XMLSchema#string

Vincenza Santoro

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the use of clozapine in individuals with developmental disabilities.

Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.

Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients.

Models for the incubation of AIDS and variations according to age and period.

Population pharmacokinetics. Theory and clinical application.

Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model.

Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables.

A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.

A clinical study of the association of antipsychotics with hyperlipidemia.

P304

463-484

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10543406.2010.547264

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221894542

http://www.w3.org/2001/XMLSchema#string

P698

22416835

http://www.w3.org/2001/XMLSchema#string